A phase 2 study of the efficacy and biomarker on the combination of transarterial chemoembolization and axitinib in the treatment of inoperable hepatocellular carcinoma.
Stephen Lam ChanWinnie YeoFrankie MoAnthony Wing-Hung ChanJane KohLeung LiEdwin P HuiCharing C N ChongPaul B S LaiTony S K MokSimon C H YuPublished in: Cancer (2017)
The combination of axitinib and TACE was potentially efficacious for patients with inoperable HCC with a high radiologic response rate. Cancer 2017;123:3977-85. © 2017 American Cancer Society.